Pharmaceuticals & Biotech/Lifesciences
FNArena Windows (Sectors)
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
Latest Stories
As bruised CSL shareholders would attest to, the biotech has been challenged. Fairmont Equities’ Michael Gable reports signs of a turnaround are in place
Sep 30 2025
Flighty investors have caused share prices to fall in 2025, but MPC Markets’ Mark Gardner sees better futures ahead for two ASX-listed companies involved in cancer prevention and treatment
Sep 23 2025
| ASX CODE | COMPANY NAME | LAST PRICE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET |
|---|---|---|---|---|---|---|
| ARX | AROA BIOSURGERY LIMITED | $0.70 | $0.82 | $0.35 | 69.4 |
$0.81 |
| AVH | AVITA MEDICAL INC | $1.63 | $4.52 | $1.27 |
$1.75 |
|
| BIO | $0.49 | $0.84 | $0.39 |
$0.95 |
||
| CSL | CSL LIMITED | $205.34 | $304.99 | $189.80 | 18.9 |
$276.819 |
| CUV | $12.67 | $14.86 | $9.41 |
$18.533 |
||
| GSS | GENETIC SIGNATURES LIMITED | $0.25 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IMM | IMMUTEP LIMITED | $0.29 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MAP | $0.09 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| MSB | MESOBLAST LIMITED | $2.67 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MVP | $0.61 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| NEU | NEUREN PHARMACEUTICALS LIMITED | $21.38 | $xx.xx | $xx.xx | xx.x | xx.xx |
| NUZ | $0.14 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| OPT | $0.60 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| PAR | $0.37 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| PNV | POLYNOVO LIMITED | $1.46 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PYC | PYC THERAPEUTICS LIMITED | $1.22 | $xx.xx | $xx.xx | xx.x | xx.xx |
| SNT | $0.03 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| TLX | TELIX PHARMACEUTICALS LIMITED | $15.17 | $xx.xx | $xx.xx | xx.x | xx.xx |
Previous Stories
Earnings Result Leaves CSL Bloodied
Aug 21 2025
Uncertain Behring growth, lower vaccine sales and a controversial restructuring plan led to a post-result share price drubbing. Is it all over for CSL?
Renewed Momentum For CSL Shares
Jul 22 2025
Michael Gable of Fairmont Equities suggests CSL shares have found a bottom and seem destined for $300-plus yet again
Treasure Chest: CSL Not A One-Trick Pony
Jul 14 2025
FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Today’s idea is on CSL
The Enigma Surrounding Clinuvel
Jul 03 2025
Clinuvel Pharmaceuticals posted a strong first half result, and offers significant upside in expanding the use of its flagship drug, but investors just aren’t excited
Rudi’s View: CSL & NextDC
May 08 2025
Your Editor attended presentations by CSL and NextDC this week
Behring Margin Outlook Still Main Game For CSL
Feb 13 2025
A weak vaccine result dragged on CSL’s H1 result but analysts focus on an improving plasma product margin and solid growth forecasts in maintaining positive views
Dr Boreham’s Crucible: Arovella Therapeutics
Aug 29 2024
The New Criterion’s Tim Boreham highlights Arovella Therapeutics in a struggling cell therapies sector worldwide
ResMed’s Margin Upside Excites
Aug 07 2024
Sleep treatment leader ResMed has faced a number of headwinds but has surprised analysts with a strong improvement in gross margins
Dr Boreham’s Crucible: Aroa Biosurgery
Jul 29 2024
Tim Boreham revisits the investment case and corporate developments for Aroa Biosurgery
CSL Shares Breaking Free
Jul 23 2024
Michael Gable of Fairmont Equities observes CSL shares are breaking through a ceiling that has held for four years, suggesting major upside potential
